{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-25-001900","form_type":"8-K","ticker":"CMPX","cik":"0001738021","company_name":"Compass Therapeutics, Inc.","filed_at":"2025-04-01T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.523567+00:00","generated_at":"2026-05-24T00:55:42.742654+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Tovecimig meets primary endpoint in Phase 2/3 BTC trial: 17.1% ORR vs 5.3% (p=0.031)","bullets":["ORR 17.1% for tovecimig+paclitaxel (19/111) vs 5.3% for paclitaxel alone (3/57), p=0.031, statistically significant.","One complete response in combo arm; progressive disease rate 16.2% vs 42.1%.","Secondary endpoints (PFS, OS, DoR) not yet mature; expected Q4 2025 after 80% event threshold.","Safety consistent with prior studies; DMC recommended continuation after four reviews.","BTC affects ~23,000 US patients annually; ~85% lack approved second-line targeted therapy."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-25-001900","json":"https://secwatch.observer/filing/0001171843-25-001900.json","markdown":"https://secwatch.observer/filing/0001171843-25-001900.md","text":"https://secwatch.observer/filing/0001171843-25-001900.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1738021/000117184325001900/0001171843-25-001900-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1738021/000117184325001900/f8k_040125.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T00:55:42.742654+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}